198 related articles for article (PubMed ID: 18556716)
1. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
Ellis SG; O'Shaughnessy CD; Martin SL; Kent K; McGarry T; Turco MA; Kereiakes DJ; Popma JJ; Friedman M; Koglin J; Stone GW;
Eur Heart J; 2008 Jul; 29(13):1625-34. PubMed ID: 18556716
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison between intracoronary beta-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis.
Schukro C; Syeda B; Kirisits C; Schmid R; Pichler P; Pokrajac B; Lang I; Pötter R; Glogar D
Radiother Oncol; 2007 Jan; 82(1):18-23. PubMed ID: 16971011
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
6. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
Hermiller JB; Raizner A; Cannon L; Gurbel PA; Kutcher MA; Wong SC; Russell ME; Ellis SG; Mehran R; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1172-9. PubMed ID: 15837245
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
Lee MS; Yang T; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
EuroIntervention; 2011 Jul; 7(3):314-22. PubMed ID: 21729833
[TBL] [Abstract][Full Text] [Related]
8. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
[TBL] [Abstract][Full Text] [Related]
9. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial.
Halkin A; Mehran R; Casey CW; Gordon P; Matthews R; Wilson BH; Leon MB; Russell ME; Ellis SG; Stone GW
Am Heart J; 2005 Dec; 150(6):1163-70. PubMed ID: 16338253
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
Moses JW; Mehran R; Nikolsky E; Lasala JM; Corey W; Albin G; Hirsch C; Leon MB; Russell ME; Ellis SG; Stone GW
J Am Coll Cardiol; 2005 Apr; 45(8):1165-71. PubMed ID: 15837244
[TBL] [Abstract][Full Text] [Related]
11. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
12. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials.
Dibra A; Kastrati A; Alfonso F; Seyfarth M; Pérez-Vizcayno MJ; Mehilli J; Schömig A
J Am Coll Cardiol; 2007 Feb; 49(5):616-23. PubMed ID: 17276188
[TBL] [Abstract][Full Text] [Related]
15. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease.
Lansky AJ; Costa RA; Mooney M; Midei MG; Lui HK; Strickland W; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1180-5. PubMed ID: 15837246
[TBL] [Abstract][Full Text] [Related]
16. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
[TBL] [Abstract][Full Text] [Related]
18. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
[TBL] [Abstract][Full Text] [Related]
19. Vascular brachytherapy for patients with drug-eluting stent restenosis.
Bonello L; Kaneshige K; De Labriolle A; Roy P; Lemesle G; Torguson R; Satler LF; Pichard AD; Lindsay J; Waksman R
J Interv Cardiol; 2008 Dec; 21(6):528-34. PubMed ID: 18973502
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction.
Karjalainen PP; Ylitalo A; Niemelä M; Kervinen K; Mäkikallio T; Pietilä M; Sia J; Tuomainen P; Nyman K; Airaksinen KE
Ann Med; 2009; 41(8):599-607. PubMed ID: 19701826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
